Literature DB >> 24390271

Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma.

Kathleen C Horst1, Katherine E Fero, Steven L Hancock, Ranjana H Advani, Debra M Ikeda, Bruce Daniel, Saul A Rosenberg, Sarah S Donaldson, Richard T Hoppe.   

Abstract

BACKGROUND: Women treated with mantle irradiation for Hodgkin lymphoma (HL) are at an increased risk of developing breast cancer (BC). Current guidelines recommend screening breast magnetic resonance imaging (MRI) as an adjunct to mammography (M) in these patients. There are limited data, however, as to the impact of breast MRI on cancer detection rates. The aim of the current study is to evaluate the use of breast MRI in survivors of HL treated and followed at a single institution.
MATERIALS AND METHODS: We retrospectively reviewed 980 female patients treated with mantle irradiation for HL between 1961 and 2008. Records were reviewed to determine age at radiotherapy treatment, radiotherapy dose, breast imaging (including M and breast MRI), biopsy results if applicable, and incidence of BC.
RESULTS: A total of 118 patients had breast imaging performed at our institution. Median age at HL diagnosis was 28 years (range, 10 to 69 y). Median radiotherapy dose was 36 Gy (range, 20 to 45 Gy). Seventy-nine patients (67%) underwent M screening only, 1 (1%) breast MRI only, and 38 (32%) both M and breast MRI. Of these 38, 19 (50%) underwent 54 screening MRI studies (range per patient=1 to 8), 13 (34%) underwent preoperative MRI for workup of BC, and 6 (16%) initiated screening MRI of the contralateral breast only after diagnosed with BC. Fifty-nine biopsies were performed: 47 were prompted by suspicious M findings only, 10 by palpable findings on physical examination (PE), and 2 by suspicious breast MRI findings. Of the 47 biopsies prompted by M, 24 revealed malignant disease, whereas 23 proved to be benign. All 10 biopsies performed by palpation were malignant. Both biopsies prompted by MRI findings were benign. With M, there were 34 true-positive findings in 32 patients, 23 false-positive findings, and 1 false-negative finding. With screening MRI, there were 2 false-positive findings, 1 false-negative finding, and no true-positive findings.
CONCLUSIONS: The role of screening breast MRI in women previously irradiated for HL is evolving. Further education of patients and physicians is important to increase awareness of more sensitive BC screening modalities in this high-risk population. Future studies are necessary to determine the appropriate integration of screening breast MRI into the ongoing follow-up of these women.

Entities:  

Mesh:

Year:  2016        PMID: 24390271      PMCID: PMC4079764          DOI: 10.1097/COC.0000000000000025

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  27 in total

1.  Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard.

Authors:  Francesco Sardanelli; Gian M Giuseppetti; Pietro Panizza; Massimo Bazzocchi; Alfonso Fausto; Giovanni Simonetti; Vincenzo Lattanzio; Alessandro Del Maschio
Journal:  AJR Am J Roentgenol       Date:  2004-10       Impact factor: 3.959

Review 2.  MR imaging of the breast for the detection, diagnosis, and staging of breast cancer.

Authors:  S G Orel; M D Schnall
Journal:  Radiology       Date:  2001-07       Impact factor: 11.105

3.  High risk of breast carcinoma after irradiation of young women with Hodgkin's disease.

Authors:  A C Aisenberg; D M Finkelstein; K P Doppke; F C Koerner; J F Boivin; C G Willett
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

4.  Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

Authors:  Andrea K Ng; M V Patricia Bernardo; Edie Weller; Kendall Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Mary Ann Stevenson; Jonathan W Friedberg; Peter M Mauch
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

5.  MRI of occult breast carcinoma in a high-risk population.

Authors:  Elizabeth A Morris; Laura Liberman; Douglas J Ballon; Mark Robson; Andrea F Abramson; Alexandra Heerdt; D David Dershaw
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

6.  Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience.

Authors:  Dietlind L Wahner-Roedler; Diana F Nelson; Ivana T Croghan; Sara J Achenbach; Cynthia S Crowson; Lynn C Hartmann; W Michael O'Fallon
Journal:  Mayo Clin Proc       Date:  2003-06       Impact factor: 7.616

7.  Breast disease: dynamic spiral MR imaging.

Authors:  B L Daniel; Y F Yen; G H Glover; D M Ikeda; R L Birdwell; A M Sawyer-Glover; J W Black; S K Plevritis; S S Jeffrey; R J Herfkens
Journal:  Radiology       Date:  1998-11       Impact factor: 11.105

8.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.

Authors:  Lois B Travis; Deirdre A Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Tom Wiklund; Charles F Lynch; Mars B Van't Veer; Ingrid Glimelius; Hans Storm; Eero Pukkala; Marilyn Stovall; Rochelle Curtis; John D Boice; Ethel Gilbert
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Breast cancer after treatment of Hodgkin's disease.

Authors:  S L Hancock; M A Tucker; R T Hoppe
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

10.  Breast cancer and other second neoplasms after childhood Hodgkin's disease.

Authors:  S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.